Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16618237 | 0.88 | MAOB (0.47) | PPARDMAPK1MAPT | |
| SCHEMBL19689391 | 0.88 | KIF11 (0.38) | SMN1; SMN2HTTKIF11SLC6A1SLC6A11 | |
| SCHEMBL19463046 | 0.88 | KIF11 (0.43) | RAB9ANPC1KIF11SLC6A1SLC6A11 | |
| SCHEMBL16618219 | 0.88 | CYP1A2 (0.38) | BACE1SMN1; SMN2HTTKIF11KMT2A | |
| SCHEMBL16624846 | 0.87 | BACE1 (0.42) | BACE1RAB9ANPC1ADORA3PPARD | |
| SCHEMBL12539335 | 0.86 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2KIF11TP53 | |
| SCHEMBL16624618 | 0.85 | FFAR1 (0.48) | RAB9APPARDSMN1; SMN2TP53 | |
| SCHEMBL2367722 | 0.84 | PPARG (0.43) | BACE1PPARDALDH1A1PPARGKDM4E | |
| SCHEMBL18102358 | 0.84 | SLC6A1 (0.38) | BACE1SMN1; SMN2HTTKIF11KMT2A | |
| SCHEMBL19463717 | 0.84 | KIF11 (0.36) | SMN1; SMN2ALDH1A1KIF11SLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2021-05-18 | — | — | US | disclosed |
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2021-05-18 | — | — | US | disclosed |
| EP-3722277-A2 | 3'END CAPS FOR RNA-INTERFERRING AGENTS FOR USE IN RNA | Novartis AG (CH) | 2020-10-14 | — | — | EP | disclosed |
| EP-3052464-B1 | 3'END CAPS FOR RNA-INTERFERRING AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| US-10519446-B2 | Organic compounds to treat hepatitis B virus | NOVARTIS AG (CH) | 2019-12-31 | — | — | US | disclosed |
| US-10519446-B2 | Organic compounds to treat hepatitis B virus | NOVARTIS AG (CH) | 2019-12-31 | — | — | US | disclosed |
| US-10227588-B2 | 3′end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2019-03-12 | — | — | US | disclosed |
| US-10227588-B2 | 3′end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2019-03-12 | — | — | US | disclosed |
| EP-3052627-B1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2018-08-22 | — | — | EP | disclosed |
| US-9988627-B2 | Formats for organic compounds for use in RNA interference | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| WO-2015050871-A2 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051044-A2 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051366-A2 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051045-A2 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051044-A2 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015050871-A2 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | disclosed |
| EP-2366785-B1 | OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT, AND USE OF THE LABELING AGENT | JAPAN SCIENCE & TECH AGENCY (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8354515-B2 | Oligonucleotide derivative, labeling agent and use for labeling agent | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20120126175-A1 | OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT AND USE FOR LABELING AGENT | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-05-24 | — | — | US | disclosed |
| EP-2366785-A1 | OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT, AND USE OF THE LABELING AGENT | Japan Science And Technology Agency (JP) | 2011-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227588-B2 | 3′end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | BACE1 4537/4885RAB9A 1149/4885NPC1 1953/4885 |
| US-20120126175-A1 | OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT AND USE FOR LABELING AGENT | UPF1, SPIN4, SRRT | BACE1 2216/4885RAB9A 4760/4885NPC1 1701/4885 |
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | BACE1 4537/4885RAB9A 1149/4885NPC1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.